Evidence map›Paper›PMID 29973077›Full record

ReviewExpert review of anticancer therapy2018

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Lingaku Lee, Tetsuhide Ito, Robert T Jensen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of anticancer therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. [Imaging of pancreatic neuroendocrine tumors].Radiologie (Heidelberg, Germany) · 2024
    Article
  15. Review
  16. Article
  17. [Neuroendocrine tumors of the pancreas].Radiologie (Heidelberg, Germany) · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lingaku Leea Department of Medicine and Bioregulatory Science , Graduate School of Medical Sciences, Kyushu University , Fukuoka , Japan.
Tetsuhide Itoc Neuroendocrine Tumor Centra, Fukuoka Sanno Hospital International University of Health and Welfare 3-6-45 Momochihama , Sawara-Ku, Fukuoka , Japan.
Robert T Jensenb Digestive Diseases Branch , NIDDK, NIH , Bethesda , MD , USA.

Funding

Diagnosis, Natural History, Management,tumor biology of Gastrinomas/PETs/Neuroendocrine tumorsZIADK053200 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 2009 to 2025
$4.3M
MANAGEMENT OF ISLET CELL TUMORSZ01DK053200 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 1990 to 2008
$667k
Intramural NIH HHS Z01 DK053200Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK053200
6 · The paper itself

Abstract

introductionRecently, there have been a number of advances in imaging pancreatic neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which have had a profound effect on the management and treatment of these patients, but in some cases are also associated with controversies. Areas covered: These advances are the result of numerous studies attempting to better define the roles of both cross-sectional imaging, endoscopic ultrasound, with or without fine-needle aspiration, and molecular imaging in both sporadic and inherited panNET syndromes; the increased attempt to develop imaging parameters that correlate with tumor classification or have prognostic value; the rapidly increasing use of molecular imaging in these tumors and the attempt to develop imaging parameters that correlate with treatment/outcome results. Each of these areas and the associated controversies are reviewed. Expert commentary: There have been numerous advances in all aspects of the imaging of panNETs, as well as other NETs, in the last few years. The advances are leading to expanded roles of imaging in the management of these patients and the results being seen in panNETs/GI-NETs with these newer techniques are already being used in more common tumors.

Indexed as

AnimalsBiopsy, Fine-NeedleDiagnostic ImagingEndosonographyHumansMolecular ImagingNeuroendocrine TumorsPancreatic NeoplasmsPrognosisCT scangastrinomaimaginginsulinomaMEN1MRINeuroendocrine tumorsomatostatin receptor imaging

Identifiers

PMID29973077
PMCPMC6283410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.